HCPLive Five at APA 2024

Clinical psychiatry is nearing a convergence of fascinating drug development with refined disease definition and diagnostics. With the late-stage progression of agents like cognition- and dementia-targeting therapies as well as psychedelics and antidepressants for depressive and mood disorders, clinicians are re-evaluating their capability to treat once improbably targets of the human psyche and cognition. All the while, the intricate pathophysiology and manifestation of psychiatric conditions are increasingly understood; the paired developments could give hope toward more individualized care in psychiatry and its neighboring fields.
Few events capture this approaching convergence as well as the American Psychiatric Association (APA) Annual Meeting, which convened in New York, NY, this month to host a bevy of sessions, discourse and new data in every subspecialty of psychiatry.
Highlighted in this latest episode of the HCPLive 5 are the biggest topics covered by HCPLive at APA 2024, featuring leading experts on the subject:
Timestamps:
00:00 Start
00:11 Roger S. McIntyre, MD on GLP-1 agonists for psychiatry
01:10 John M. Oldham, MD, MS on new guidelines for personality disorders
02:21 Brian Barnett, MD on psychedelics for substance use disorders
03:21 Katharine Phillips, MD on differentiating between OCD and body dysmorphic disorder
04:33 Davangere P. Devanand, MD on the value of lecanemab and other dementia therapies
Check out more APA coverage: www.hcplive.com/conference/apa
#psychiatry #mentalhealth #conference